A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia

International Journal of Hyperthermia

Volumn 19, Issue 4, 2003, Pages 402-413

  Van Vulpen, M ^a   De Leeuw, J R J ^a   Van Gellekom, M P R ^a   Van Der Hoeven, J ^a   De Graeff, A ^a   Van Moorselaar, R J A ^a   Van Der Tweel, I ^b   Hofman, P ^a   Lagendijk, J J W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Hyperthermia; Prostate cancer; Quality of life; Radiotherapy

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANALYSIS OF VARIANCE; ARTICLE; BASAL BODY TEMPERATURE; BEAM THERAPY; BLADDER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; ENTERITIS; FATIGUE; FUNCTIONAL ASSESSMENT; HEALTH CARE COST; HEALTH SURVEY; HUMAN; HYPERTHERMIC THERAPY; INTERSTITIUM; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MENTAL DISEASE; PAIN; PHYSICAL DISEASE; PROSPECTIVE STUDY; PROSTATE CARCINOMA; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; RADIATION FIELD; RECTUM DISEASE; RECTUM TEMPERATURE; SAFETY; SEXUAL BEHAVIOR; URINARY TRACT DISEASE;

AGED; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY;

EID: 0037715337     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.1080/0265673031000063855     Document Type: Article

References (48)

1. Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44: 809-19.
2. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Long CC, Fuks Z. Dose escalation with three-dimensional confromal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491-500.
3. Hanks GE, Hanlon AL, Schultheis TE, Pinover WH, Movsas B, Epstein BE, Hunt MA. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998; 41: 501-10.
4. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
5. Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001; 49: 947-56.
6. Kaplan ID, Prestige BR, Bagshaw MA, Cox RS. The importance of local control in the treatment of prostatic cancer. J Urol 1992; 147: 917-21.
7. Kuban DA, El-Mahdi AM, Schellhammer PF. Potential benefit of improved local tumor control in patients with prostatic carcinoma. Cancer 1995; 75: 2373-82.
8. Coen JJ, Zietman AL, Thakral H, Shipley WU. Links radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases. J Clin Oncol 2002; 20: 3199-205.
9. Anscher MS, Samulski TV, Dodge RD, Prosnitz LR, Dewhirst MW. Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997; 37: 1059-65.
10. Algan O, Fosmire H, Hynynen K, Dalkin B, Cui H, Drach G, Stea B, Cassady JR. External beam radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate carcinoma. Cancer 2000; 89: 399-403.
11. Kalapurakal JA, Mittal BB, Sathiaseelan V. Re-irradiation and external hyperthermia in locally advanced radiation recurrent, hormone refractory prostate cancer: A preliminary report. Br J Radiol 2001; 74: 745-51.
12. Kaver I, Koontz WW Jr, Wilson JD, Guice JM, Ware JL. The effect of radiation therapy and hyperthermia on a human prostatic carcinoma cell line growth in athymic nude mice. J Urol 1991; 145: 654-6.
13. Peschke P, Hahn EW, Wolber G, Hildenbrand D, Zuna I. Interstitial radiation and hyperthermia in the Dunning R3327 prostate tumours model: Therapeutic efficacy depends on radiation dose-rate, sequence and frequency of heating. Int J Radiat Biol 1996; 70: 609-16.
14. Ryu S, Brown SL, Kim SH, Khil MS, Kim JH. Preferential radiosensitization of human prostatic carcinoma cells by mild hyperthermia. Int J Radiat Oncol Biol Phys 1996; 34: 133-8.
15. Prionas SD, Kapp DS, Goffinet DR, Ben-Yosef R, Fessendren P, Bagshaw MA. Thermometry of interstitial hyperthermia given as an adjuvant to brachytherapy for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1994; 28: 151-62.
16. Van Vulpen M, Raaymakers BW, Lagendijk JJ, Creeze J, De Leeuw AA, Van Moorselaar JR, Ligtvoet CM, Battermann JJ. 3D controlled interstitial hyperthermia combined with radiotherapy for locally advanced prostate carcinoma, a feasibility study. Int J Radiat Oncol Biol Phys 2002; 53: 116-26.
17. Petrovich Z, Emami B, Kapp D, Sapozink MD, Langholz B, Oleson J, Lieskovsky G, Astrahan M. Regional hyperthermia in patients with recurrent genitourinary cancer. Am J Clin Oncol 1991; 14: 472-7.
18. Van Vulpen M, De Leeuw AAC, Van De Kamer JB, Kroeze H, Boon TA, Wárlám-Rodenhuis CC, Lagendijk JJW, Battermann JJ. Regional hyperthermia combined with radiotherapy for locally advanced prostate carcinoma, a feasibility study. Int J Hyperthermia, submitted.
19. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, De Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in the oncology. J Natl Cancer Inst 1993; 85: 365-76.
20. Calais Da Silva F. Quality of life in prostate cancer patients. Cancer 1993; 72: 3803-6.
21. Lim AJ, Brandon AH, Fiedler J, Brickmanf AL, Boyer CI, Raub WA Jr, Soloway MS. Quality of life: Radical prostatectomy versus radiation therapy for prostate cancer. J Urol 1995; 154: 1420-5.
22. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129-35.
23. Altwein J, Ekman P, Barry M, Biermann C, Carlsson P, Fossa S, Kiebert G, Kuchler T, McLeod D, Porter A, Steineck G. How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium. Urology 1997; 49 (4A Suppl): 66-76.
24. Litwin MS, Fitzpatrick JM, Fossa SD, Newling D.W. NewDefining an international research agenda for quality of life in men with prostate cancer. Prostate 1999; 41: 58-67.
25. Joly F, Brune D, Couette JE, Lesaunier F, Heron JF, Peny J, Henry-Amar M. Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. Ann Oncol 1998; 9: 751-7.
26. Lilleby W, Fossa SD, Waehre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43: 735-43.
27. Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial bracytherapy. Int J Radiat Oncol Biol Phys 2001; 51: 614-23.
28. Bacon CG, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 2001; 166: 1804-10.
29. Madalinska JB, Essink-Bot ML, De Koning HJ, Kirkels WJ, Van Der Maas PJ, Schroder FH. Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate 2001; 46: 87-97.
30. D'Amico AV, Chang H, Holupka E, Renshaw A, Desjarden A, Chen M, Loughlin KR, Richie JP. Calculated prostate cancer volume: The optimal predictor of actual cancer volume and pathologic stage. Urology 1997; 49: 385-91.
31. D'Amico AV, Whittington R, Kaplan I, Beard C, Schultz D, Malkowicz SB, Wein A, Tomaszewski JE, Coleman CN. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter. Cancer 1998; 82: 334-41.
32. Skwarchuk MW, Jackson A, Zelefsky MJ, Venkatraman ES, Cowen DM, Levegrun S, Burman CM, Fuks Z, Leibel SA, Ling CC. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response. Int J Radiat Oncol 2000; 47: 103-13.
33. Trotti A. The evolution and application of toxicity criteria. Semin Radiat Oncol 2002; 12 (1 Suppl 1): 1-3.
34. ICRU Report No. 50. International Commission on Radiation Units and Measurements Prescribing, Recording, and reporting Photon Beam Therapy. Washington, DC: International Commission on Radiation Units and Measurements, 1993.
35. Hornbrook MC, Goodman MJ. Assessing relative health plan ris with the Rand 36 health survey. Inquiry 1995; 32: 56-74.
36. Borghede G, Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30. Qual Life Res 1996; 5: 212-22.
37. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-44.
38. Tait DM, Nahum AE, Meyer LC, Law M, Dearnaley DP, Horwich A, Mayles WP, Yarnold JR. Acute toxicity in pelvic radiotherapy; A randomised trial of conformal versus conventional treatment. Radiother Oncol 1997; 42: 121-36.
39. Nunnally JC, Berstein IH. Psychometric Theory. New York: McGraw-Hill, 1994.
40. Hanlon AL, Watkins Brunner D, Peter R, Hanks GE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: Comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 2001; 49: 51-9.
41. Janda M, Gerstner N, Obermair A, Fuerst A, Wachter S, Dieckmann K, Potter R. Quality of life changes during conformal radiation therpay for prostate carcinoma. Cancer 2000; 89: 1322-8.
42. Clark JA, Rieker P, Propert KJ, Talcott JA. Changes in quality of life following treatment for early prostate cancer. Urology 1999; 53: 161-8.
43. Lubeck DP, Litwin MS, Henning JM, Stoddard ML, Flanders SC, Carroll PR. Changes in health-related quality of life in the first year after treatment for prostate cancer: Results from CaPSURE. Urology 1999; 53: 180-6.
44. Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localized prostate cancer: Differences based on treatment modality. J Urol 2001; 166: 947-52.
45. Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate carcinoma: An examination of treatment-related, demographic, and psychosocial factors. Cancer 2001; 92: 151-9.
46. Kupelian PA, Reddy CA, Klein EA, Willoughby TR. Short-course intensity-modulated radiotherapy (70 GY at 2.5 Gy per fraction) for localized prostate cancer: Preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001; 51: 988-93.
47. Beard CJ, Propert KJ, Rieker PP, Clark JA, Kaplan I, Kantoff PW, Talcott JA. Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: A prospective multiinstitutional outcomes study. J Clin Oncol 1997; 15: 223-9.
48. Lubeck DP, Grossfeld GD, Carroll PR. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 2001; 58 (2 Suppl 1): 94-100.